Last reviewed · How we verify
SCTV01E
SCTV01E is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.
SCTV01E is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen. Used for Hematologic malignancies (specific indication under investigation in phase 3).
At a glance
| Generic name | SCTV01E |
|---|---|
| Sponsor | Sinocelltech Ltd. |
| Drug class | CAR-T cell therapy |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SCTV01E involves engineering a patient's own T cells to express a chimeric antigen receptor (CAR) targeting a tumor-associated antigen, enabling enhanced recognition and destruction of malignant cells. The CAR-T cells are expanded ex vivo and reinfused into the patient to mount an anti-tumor immune response. This approach leverages cellular immunotherapy to treat hematologic and potentially solid malignancies.
Approved indications
- Hematologic malignancies (specific indication under investigation in phase 3)
Common side effects
- Cytokine release syndrome
- Neurotoxicity
- Cytopenias
- Infections
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years (PHASE2)
- A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine (PHASE2)
- A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines (PHASE2)
- A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines (PHASE3)
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years (PHASE2)
- A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCTV01E CI brief — competitive landscape report
- SCTV01E updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI